Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models
- 12 January 2011
- journal article
- Published by Wiley in Cancer Science
- Vol. 102 (3), 614-621
- https://doi.org/10.1111/j.1349-7006.2010.01834.x
Abstract
Antitumor activities of YM155, a novel small-molecule survivin suppressant, were investigated in a wide variety of human cancer cell lines and xenograft models. YM155 inhibited the growth of 119 human cancer cell lines, with the greatest activity in lines derived from non-Hodgkin's lymphoma, hormone-refractory prostate cancer, ovarian cancer, sarcoma, non-small-cell lung cancer, breast cancer, leukemia and melanoma. The mean log growth inhibition of 50% (GI(50) ) value was 15 nM. The mean GI(50) values of YM155 were 11 nM for p53 mut/null cell lines and 16 nM for p53 WT cell lines, suggesting that YM155 inhibits the growth of human tumor cell lines regardless of their p53 status. In non-small-cell lung cancer (Calu 6, NCI-H358), melanoma (A375), breast cancer (MDA-MB-231) and bladder cancer (UM-UC-3) xenograft models, 3- or 7-day continuous infusions of YM155 (1-10 mg/kg) demonstrated significant antitumor activity without showing significant bodyweight loss. Tumor regressions induced by YM155 were associated with reduced intratumoral survivin expression levels, increased apoptosis and decreased mitotic indices. The broad and potent antitumor activity presented in the present study is indicative of the therapeutic potential of YM155 in the clinical setting.Keywords
This publication has 34 references indexed in Scilit:
- Characterization of Human Organic Cation Transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-Mediated Transport of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small Molecule Survivin SuppressantDrug Metabolism and Disposition, 2009
- Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma CellsDrug Metabolism and Disposition, 2008
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of SurvivinJournal of Clinical Oncology, 2008
- siRNA Directed Against Survivin Enhances Pancreatic Cancer Cell Gemcitabine ChemosensitivityDigestive Diseases and Sciences, 2008
- YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor XenograftsCancer Research, 2007
- Targeting survivin in cancer therapy: fulfilled promises and open questionsCarcinogenesis: Integrative Cancer Research, 2007
- Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNACancer Letters, 2006
- Survivin Is an Independent Prognostic Marker for Risk Stratification of Breast Cancer PatientsClinical Chemistry, 2004
- The IARC TP53 database: New online mutation analysis and recommendations to usersHuman Mutation, 2002
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990